Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
- PMID: 34430554
- PMCID: PMC8350658
- DOI: 10.21037/atm-21-1103
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/atm-21-1103). DVS is the co-founder and President of Prolynx, which developed PLX038. LC and FCB will act as investigators in a forthcoming clinical trial of PLX038. The authors have no other conflicts of interest to declare.
Comment on
-
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
References
-
- Hurvitz SA, Tolaney SM, Punie K, et al. Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Cancer Res 2021;81:GS3-06.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources